LAG3 Expression in Triple Negative Breast Cancer

Samsung Medical Center128 enrolled

Overview

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

128

Conditions

Triple Negative Breast Cancer Immune Checkpoint Inhibitor

Interventions

LAG-3 expression / immune checkpoint protein expressionPROCEDURE

Evaluate the tissue and blood before and after chemotherapy

Eligibility

Sex: FEMALEHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Planned neoadjuvant chemotherapy * Triple negative breast cancer Exclusion Criteria: * HER2-positive breast cancer * Hormone receptor positive breast cancer

Locations (1)

Ji-Yeon Kim

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

LAG-3 expression/immune checkpoint preotein expression

Relationship neoadjuvant chemotherapy plus immune checkpoint inhibitor

Time frame: Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgery

Central Contacts

Ji-Yeon Kim

CONTACT

82-2-3410-3459 jyeon25@skku.edu

Mee Ryung Hong

CONTACT

82-2-2148-7147 ring7629@naver.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.